Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

isone and in 10% of patients treated with irofulven + prednisone. No PSA responses were observed following treatment with mitoxantrone + prednisone. Treatment related toxicity including Grade 3-4 myelosuppression was manageable in all 3 arms. These results support further study of irofulven in this setting.

Additional Abstracts Presented at the 2007 ASCO Annual Meeting

Abstract # 7080

"Changing the treatment paradigm for patients with MDS: how the development of therapeutics influences population-based care in community oncology - the Georgia Cancer Specialists Outcomes Database experience"

Abstract # 7088

"Phase II trial of decitabine in myelofibrosis with myeloid metaplasia"

Abstract # 9565

"Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): A Children's Oncology Group Study"

Abstract # 2036

"Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme"

Abstract #34157

"A retrospective safety and efficacy analysis of combination therapy for GBM using temozolomide, external beam radiation (EBRT), and Gliadel Wafers"

About Aloxi(R) Injection

Aloxi is approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Aloxi is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderately emetogenic cancer chemotherapy. In clinical trials, the most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Please see t
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , , SAN DIEGO , Jan. 15 ... entry of a settlement agreement which will resolve the consolidated securities ... Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay ... the company has agreed to issue to the plaintiffs, class a ...
... , , , , , , ... Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has relocated its headquarters to its new buildings,in ...
Cached Medicine Technology:Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 2Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 3Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 4China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 2China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 3
(Date:7/30/2014)... According to the market research report ... Technology (ICS, MES, ERP, ITS), Field Devices, Products ... (Process, Discrete) - Global Forecast & Analysis to ... market is expected to reach $6.99 Billion at ... 70 market data Tables and 96 Figures spread ...
(Date:7/30/2014)... 2014 “Today, we have said ¡Basta! ... are being promoted to our children and our families. ... the beverage industry to put the health of people ... Jane L. Delgado, President and CEO of the National ... Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman Rosa L. ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 “North America ... market data on the North America Contrast Media Injectors ... dollars, and volume (in units) and average price data ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and MRI ... contrast agent) is a substance used to enhance the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The Dr. ... Spohn Health, recently announced the proposed naming of the ... Dr. Hector P. Garcia Family Health Center. , The ... health care services, including comprehensive chronic disease management programs, ... also be a pioneering medical home model center. , ...
(Date:7/30/2014)... Decene is an alkene with ... ten carbon atoms with one double bond. 1-Decene ... It can be used as a co-monomer in ... epoxides, amines, oxo alcohols, synthetic lubricants, synthetic fatty ... will receive 10% customization on this report. , ...
Breaking Medicine News(10 mins):Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Dr. Hector P Garcia Memorial Foundation Supports New Health Care Facility 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4
... TXStudents, perceptions of their overall experience on campus may ... research has also found a solid relationship between undergraduates, ... quality of life. Are campus green spaces as important ... new study investigating this question revealed some interesting insights. ...
... rule out men who don,t need treatment , MONDAY, ... the standard prostate cancer test can help improve predictions ... report. , The basic test measures blood levels of ... cells. But the standard PSA test cannot distinguish between ...
... 1st Plumbing ... Austin, Texas. The Easy Water system is a revolutionary alternative to salt-based water softeners. The ... your water, without them resulting in hard water buildup. , ... Austin, Texas -- 1st Plumbing Services has been selected as ...
... observational studies show an increased risk for cancer among ... may be worse than currently known. "As ... to see the current disparity in knowledge and outcomes ... of the Institute for Health Promotion Research at the ...
... lung cancer clinical trial to guide targeted therapies to ... a step toward personalized care and more effective, efficient ... during the American Association for Cancer Research 101st Annual ... M. D. Anderson Cancer Center presented the results of ...
... black children in kindergarten, first grade , MONDAY, April ... urban elementary school children, U.S. researchers report. , They ... 44 schools across the bi-state Kansas City metropolitan area, ... with the fungus ( T. tonsurans ) that causes ...
Cached Medicine News:Health News:Campus green space more important for undergrads 2Health News:New Test May Predict Prostate Cancer's Aggressiveness 2Health News:New Test May Predict Prostate Cancer's Aggressiveness 3Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 2Health News:1st Plumbing Services Selected to be Exclusive Dealer in Austin, Texas for Installation of Easy Water No-Salt Water Conditioning System 3Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 2Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 3Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 4Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 5Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 6Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 7Health News:BATTLE links potential biomarkers to drugs for lung cancer 2Health News:BATTLE links potential biomarkers to drugs for lung cancer 3Health News:BATTLE links potential biomarkers to drugs for lung cancer 4Health News:Resistant Ringworm Common in Urban Elementary Schools 2
... AFO is designed to treat or help ... immobility such as hip displasia, foot drop, ... A comfortable Kodel lining provides a comfortable ... anti-rotation bar is easily rotated and locked ...
... RCAI provides adjustable static stretch of the ... as diminished foot and ankle range of ... straps attached to the sides of the ... be controlled, as needed, in the desired ...
... Splint is indicated for the treatment of ... economical and easy to apply. The splint ... dorsiflexion, limiting nightly contractures and tightening of ... feature permits flexibility in the treatment of ...
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
Medicine Products: